By

Lundbeckfonden
Funds further company’s mission to identify and de-risk preclinical rare disease therapeutics, ultimately, spinning out companies with IND-ready programs – Cydan expands leadership team with new chief medical officer and vice president of development Cambridge, Mass., October 17, 2017 – Cydan today announced a new round of financing, raising a committed total of $34 million to advance the company’s...
Lund, Sweden, 12.00 CEST, 13 October 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces the appointment of Helena L Brandt as its new Head of Human Resources. Her appointment is to meet the...
Highly experienced clinical drug developer to oversee R&D functions and Companys Phase 3 development program New Haven, CT, October 12, 2017 – Trevi Therapeutics, Inc. (“Trevi” or the “Company”), a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch), today announced that it has hired Helena Brett-Smith, M.D., as Chief Development Officer. Dr. Brett-Smith has more than...
Clinical Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Additional Nonclinical Data Show APX001 is Effective Against a Broad Range of Pathogenic Fungi, Including Deadly Candida auris SAN DIEGO – October 9, 2017 – Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001,...
Lund, Sweden, 08:00 CEST 9 October 2017 – BONESUPPORT™ an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces that the first patient has been recruited in a study evaluating CERAMENT® G and CERAMENT® V in...
Favorable Pharmacokinetic and Safety Data for SPR741 Observed at Doses Exceeding the Anticipated Phase 2 Dose Range CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced data from the Company’s Phase 1 single...
Lund, Sweden, 18:00 CEST 29th September 2017 – During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 29th September, 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,650,651. For more information contact: Richard Davies, CEO...
SAN DIEGO, Sept. 21, 2017 /PRNewswire/ — Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that seven posters from the APX001 development program will be presented at the Infectious Diseases Society of America (IDSA) IDWeek 2017, being held in San Diego, CA, from October 4 to 8, 2017. For the first time, the...
BONESUPPORT APPOINTS JERRY CHANG AS EXECUTIVE VICE PRESIDENT OF RESEARCH & DEVELOPMENT Lund, Sweden, 12.00 CEST, 19 September 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has appointed...
Copenhagen, Denmark – August 29th, 2017: Danish-based Dermtreat today announced the GMP (Good Manufacturing Practices) approval for the production of its novel Rivelin® patch – a breakthrough therapy in treating mucosal diseases. Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical...
1 2